Rhee Ki-Jong, Lee Chang Gun, Kim Sung Woo, Gim Dong-Hyeon, Kim Hyun-Cheol, Jung Bae Dong
1. Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University at Wonju.
2. Department of Animal Science, North Carolina State University.
Int J Med Sci. 2015 Nov 23;12(12):987-94. doi: 10.7150/ijms.13339. eCollection 2015.
Diabetes mellitus (DM) is caused by either destruction of pancreatic β-cells (type 1 DM) or unresponsiveness to insulin (type 2 DM). Conventional therapies for diabetes mellitus have been developed but still needs improvement. Many diabetic patients have complemented conventional therapy with alternative methods including oral supplementation of natural products. In this study, we assessed whether Ginkgo biloba extract (EGb) 761 could provide beneficial effects in the streptozotocin-induced type 1 DM and high-fat diet-induced type 2 DM murine model system. For the type 1 DM model, streptozotocin-induced mice were orally administered EGb 761 for 10 days prior to streptozotocin injection and then again administered EGb 761 for an additional 10 days. Streptozotocin-treated mice administered EGb 761 exhibited lower blood triglyceride levels, lower blood glucose levels and higher blood insulin levels compared to streptozotocin-treated mice. Furthermore, liver LPL and liver PPAR-α were increased whereas IL-1β and TNF-α were decreased in streptozotocin-injected mice treated with EGb 761 compared to mice injected with streptozotocin alone. For the type 2 DM model, mice were given high-fat diet for 60 days and then orally administered EGb 761 every other day for 80 days. We found that mice given a high-fat diet and EGb 761 showed decreased blood triglyceride levels, increased liver LPL, increased liver PPAR-α and decreased body weight compared to mice given high-fat diet alone. These results suggest that EGb 761 can exert protective effects in both type 1 and type 2 DM murine models.
糖尿病（DM）是由胰腺β细胞破坏（1型糖尿病）或对胰岛素无反应（2型糖尿病）引起的。糖尿病的传统疗法已经得到发展，但仍需改进。许多糖尿病患者用包括口服天然产物在内的替代方法补充传统疗法。在本研究中，我们评估了银杏叶提取物（EGb）761是否能在链脲佐菌素诱导的1型糖尿病和高脂饮食诱导的2型糖尿病小鼠模型系统中发挥有益作用。对于1型糖尿病模型，在注射链脲佐菌素前10天对链脲佐菌素诱导的小鼠口服给予EGb 761，然后再额外给予EGb 761 10天。与仅接受链脲佐菌素治疗的小鼠相比，接受EGb 761治疗的链脲佐菌素处理小鼠的血液甘油三酯水平较低、血糖水平较低且血液胰岛素水平较高。此外，与仅注射链脲佐菌素的小鼠相比，用EGb 761治疗的链脲佐菌素注射小鼠的肝脏脂蛋白脂肪酶（LPL）和肝脏过氧化物酶体增殖物激活受体α（PPAR-α）增加，而白细胞介素-1β（IL-1β）和肿瘤坏死因子-α（TNF-α）减少。对于2型糖尿病模型，小鼠给予高脂饮食60天，然后每隔一天口服给予EGb 761 80天。我们发现，与仅给予高脂饮食的小鼠相比，给予高脂饮食和EGb 761的小鼠血液甘油三酯水平降低、肝脏LPL增加、肝脏PPAR-α增加且体重减轻。这些结果表明，EGb 761在1型和2型糖尿病小鼠模型中均可发挥保护作用。
